GC Biopharma Corp. (KRX:006280)

GC Biopharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	84,183	22,563	49,706	105,366	186,060	232,288
Short-Term Investments	-0	0	0	-0	-	-
Trading Asset Securities	1,432	1,432	5,800	6,940	16,875	23,210
Cash & Short-Term Investments	85,615	23,995	55,506	112,306	202,935	255,498
Cash Growth	9.63%	-56.77%	-50.58%	-44.66%	-20.57%	80.53%
Accounts Receivable	438,657	386,526	436,957	394,155	413,817	402,088
Other Receivables	14,113	9,635	11,976	13,778	9,624	20,598
Receivables	457,098	404,812	450,933	409,433	423,987	422,736
Inventory	886,696	746,582	516,245	442,408	454,976	437,071
Prepaid Expenses	10,353	9,638	4,147	4,157	3,275	9,513
Other Current Assets	14,382	16,806	12,316	12,133	5,346	7,223
Total Current Assets	1,454,145	1,201,833	1,039,148	980,437	1,090,519	1,132,042
Property, Plant & Equipment	924,757	915,826	952,703	930,822	899,847	751,099
Long-Term Investments	199,373	225,340	206,646	216,273	110,962	92,030
Goodwill	-	125,614	142,475	142,475	142,475	10,065
Other Intangible Assets	423,008	72,535	86,166	76,735	57,240	31,797
Long-Term Deferred Tax Assets	61,199	49,941	35,185	27,839	19,832	20,686
Long-Term Deferred Charges	-	109,236	109,240	92,353	77,691	67,702
Other Long-Term Assets	38,112	43,272	68,972	53,824	63,299	45,700
Total Assets	3,100,873	2,743,876	2,643,314	2,525,537	2,462,145	2,151,400
Accounts Payable	170,667	156,818	143,816	121,270	119,541	134,785
Accrued Expenses	37,246	40,073	34,000	102,066	85,781	82,684
Short-Term Debt	521,579	367,092	315,447	182,000	104,836	203,200
Current Portion of Long-Term Debt	253,469	10,829	202,813	5,416	120,539	91,175
Current Portion of Leases	14,629	14,304	14,335	11,580	9,887	7,505
Current Income Taxes Payable	8,531	7,873	2,041	17,158	28,338	11,663
Current Unearned Revenue	480	2,025	1,629	7,084	7,730	582
Other Current Liabilities	211,125	170,461	154,835	94,165	76,231	57,810
Total Current Liabilities	1,217,726	769,475	868,917	540,738	552,883	589,403
Long-Term Debt	231,848	339,506	84,891	278,797	280,343	194,160
Long-Term Leases	100,490	96,412	106,536	97,751	90,969	70,392
Long-Term Unearned Revenue	7,370	7,400	7,500	14,049	16,296	5,606
Long-Term Deferred Tax Liabilities	12,938	4,063	2,213	1,358	1,869	1,876
Other Long-Term Liabilities	29,619	29,200	32,038	25,031	18,531	14,946
Total Liabilities	1,633,027	1,262,860	1,103,451	958,895	962,388	882,094
Common Stock	58,433	58,433	58,433	58,433	58,433	58,433
Additional Paid-In Capital	396,224	396,220	393,605	393,531	385,821	337,016
Retained Earnings	865,900	815,336	872,989	903,467	867,353	757,278
Treasury Stock	-35,702	-35,702	-35,702	-35,702	-35,702	-35,702
Comprehensive Income & Other	-5,058	18,358	10,912	8,394	-1,134	1,498
Total Common Equity	1,279,797	1,252,645	1,300,236	1,328,122	1,274,771	1,118,524
Minority Interest	188,048	228,371	239,627	238,520	224,987	150,782
Shareholders' Equity	1,467,846	1,481,016	1,539,863	1,566,642	1,499,757	1,269,306
Total Liabilities & Equity	3,100,873	2,743,876	2,643,314	2,525,537	2,462,145	2,151,400
Total Debt	1,122,015	828,142	724,022	575,543	606,574	566,432
Net Cash (Debt)	-1,036,400	-804,147	-668,516	-463,238	-403,639	-310,934
Net Cash Per Share	-90807.31	-70457.79	-58574.02	-40587.96	-35366.01	-27243.38
Filing Date Shares Outstanding	11.41	11.41	11.41	11.41	11.41	11.41
Total Common Shares Outstanding	11.41	11.41	11.41	11.41	11.41	11.41
Working Capital	236,419	432,358	170,231	439,698	537,637	542,639
Book Value Per Share	112133.29	109754.26	113924.12	116367.45	111692.86	98002.82
Tangible Book Value	856,790	1,054,496	1,071,595	1,108,912	1,075,056	1,076,662
Tangible Book Value Per Share	75070.21	92392.82	93891.05	97160.69	94194.24	94334.96
Land	-	17,509	17,346	17,383	18,025	17,976
Buildings	-	705,071	695,794	638,353	572,756	508,734
Machinery	-	430,546	407,055	369,503	333,326	310,115
Construction In Progress	-	43,028	59,224	103,334	150,176	85,095

Source: S&P Global Market Intelligence. Standard template. Financial Sources.